Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice (original) (raw)

• International Diabetes Federation. IDF Diabetes Atlas 10th edn (IDF, 2021).
• Franks, P. W. & Poveda, A. Lifestyle and precision diabetes medicine: will genomics help optimise the prediction, prevention and treatment of type 2 diabetes through lifestyle therapy? Diabetologia 60, 784–792 (2017).
  Article PubMed PubMed Central Google Scholar
• Chan, J. C. N. et al. The Lancet Commission on Diabetes: using data to transform diabetes care and patient lives. Lancet 396, 2019–2082 (2021).
  Article PubMed Google Scholar
• GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249 (2020).
  Article Google Scholar
• Magliano, D. J. et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019).
  Article PubMed PubMed Central Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41, 917–928 (2018).
  Article PubMed Central Google Scholar
• Magliano, D. J., Martin, V. J., Owen, A. J., Zomer, E. & Liew, D. The productivity burden of diabetes at a population level. Diabetes Care 41, 979–984 (2018).
  Article PubMed Google Scholar
• Gregg, E. W., Hora, I. & Benoit, S. R. Resurgence in diabetes-related complications. JAMA 321, 1867–1868 (2019).
  Article PubMed Google Scholar
• Rossing, P. et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 102, 990–999 (2022).
  Article PubMed Google Scholar
• Draznin, B. et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022. Diabetes Care 45, S46–S59 (2022).
  Article Google Scholar
• Flegal, K. M., Kit, B. K., Orpana, H. & Graubard, B. I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309, 71–82 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, Y. H. et al. Underweight increases the risk of end-stage renal diseases for type 2 diabetes in Korean population: data from the national health insurance service health checkups 2009–2017. Diabetes Care 43, 1118–1125 (2020).
  Article CAS PubMed Google Scholar
• Yokomichi, H. et al. All-cause and cardiovascular disease mortality in underweight patients with diabetic nephropathy: BioBank Japan cohort. J. Diabetes Investig. 12, 1425–1429 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Di Angelantonio, E. et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314, 52–60 (2015).
  Article PubMed Google Scholar
• Magliano, D. J. et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes Endocrinol. 10, 112–119 (2022).
  Article PubMed Google Scholar
• Harding, J. L., Pavkov, M. E., Gregg, E. W. & Burrows, N. R. Trends of nontraumatic lower-extremity amputation in end-stage renal disease and diabetes: United States, 2000–2015. Diabetes Care 42, 1430–1435 (2019).
  Article PubMed Google Scholar
• Ling, W. et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. Cardiovasc. Diabetol. 19, 182 (2020).
  Article PubMed PubMed Central Google Scholar
• Wu, H. et al. Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study. Cardiovasc. Diabetol. 19, 60 (2020).
  Article PubMed PubMed Central Google Scholar
• Ali, M. K., Pearson-Stuttard, J., Selvin, E. & Gregg, E. W. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia 65, 3–13 (2022).
  Article PubMed Google Scholar
• Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
  Article PubMed Google Scholar
• Wu, H. et al. Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study. Diabetologia 63, 757–766 (2020).
  Article CAS PubMed Google Scholar
• Norhammar, A. et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries. Diabetes Obes. Metab. 24, 1277–1287 (2022).
  Article PubMed PubMed Central Google Scholar
• Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
  Article PubMed Google Scholar
• Xiong, X. F. et al. Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: a two-step cluster analysis. J. Diabetes Investig. 12, 1346–1358 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Grundy, S. M. et al. Diabetes and cardiovascular disease. Circulation 100, 1134–1146 (1999).
  Article CAS PubMed Google Scholar
• Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular disease. the Framingham study. JAMA 241, 2035–2038 (1979).
  Article CAS PubMed Google Scholar
• American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S144–s174 (2022).
  Article Google Scholar
• Poznyak, A. et al. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int. J. Mol. Sci. 21, 1835 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Creager, M. A., LüScher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and vascular disease. Circulation 108, 1527–1532 (2003).
  Article PubMed Google Scholar
• Giugliano, D., Maiorino, M. I., Bellastella, G. & Esposito, K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc. Diabetol. 20, 36 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Giugliano, D., Maiorino, M. I., Bellastella, G. & Esposito, K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine 61, 23–27 (2018).
  Article CAS PubMed Google Scholar
• Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
  Article CAS PubMed Google Scholar
• Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
  Article CAS PubMed Google Scholar
• Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
  Article CAS PubMed Google Scholar
• Cherney, D. Z., Kanbay, M. & Lovshin, J. A. Renal physiology of glucose handling and therapeutic implications. Nephrol. Dial. Transplant. 35 (Suppl. 1), i3–i12 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Kashiwagi, A. & Maegawa, H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J. Diabetes Investig. 8, 416–427 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Thomas, M. C. & Cherney, D. Z. I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61, 2098–2107 (2018).
  Article CAS PubMed Google Scholar
• Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356–363 (2018).
  Article CAS PubMed Google Scholar
• Hilton, P. J. Na+ transport in hypertension. Diabetes Care 14, 233–239 (1991).
  Article CAS PubMed Google Scholar
• Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Tomita, I. et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 32, 404–419.e6 (2020).
  Article CAS PubMed Google Scholar
• Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015).
  Article CAS PubMed Google Scholar
• Drucker, D. J. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24, 15–30 (2016).
  Article CAS PubMed Google Scholar
• Burgmaier, M. et al. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe-/- mice. Atherosclerosis 231, 427–435 (2013).
  Article CAS PubMed Google Scholar
• Nyström, T. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, E1209–1215 (2004).
  Article PubMed Google Scholar
• Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
  Article CAS PubMed Google Scholar
• Joseph, J. J. et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145, e722–e759 (2022).
  Article PubMed Google Scholar
• Emdin, C. A. et al. Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 313, 603–615 (2015).
  Article PubMed Google Scholar
• Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
  Article PubMed Google Scholar
• Wright, J. T. Jr et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
  Article CAS PubMed Google Scholar
• Buckley, L. F. et al. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. Diabetes Obes. Metab. 20, 1499–1502 (2018).
  Article CAS PubMed Google Scholar
• Kearney, P. M. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117–125 (2008).
  Article CAS PubMed Google Scholar
• Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
  Article CAS PubMed Google Scholar
• Giugliano, R. P. et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus. Circulation 137, 1571–1582 (2018).
  Article CAS PubMed Google Scholar
• Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005); erratum 368, 1415 (2006).
• Chew, E. Y. et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233–244 (2010).
  Article PubMed Google Scholar
• Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
  Article CAS PubMed Google Scholar
• Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941–950 (2017).
  Article CAS PubMed Google Scholar
• Ray, K. K. et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 7, 618–628 (2019).
  Article CAS PubMed Google Scholar
• Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).
  Article CAS PubMed Google Scholar
• Reaven, P. D. et al. Intensive glucose control in patients with type 2 diabetes — 15-year follow-up. N. Engl. J. Med. 380, 2215–2224 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52, 2288–2298 (2009).
  Article CAS PubMed Google Scholar
• Barer, Y., Cohen, O. & Cukierman-Yaffe, T. Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: a systematic review and meta-analysis. Diabetes Obes. Metab. 21, 732–735 (2019).
  Article PubMed Google Scholar
• Wong, M. G., Heerspink, H. J. L. & Perkovic, V. ACCORDION: ensuring that we hear the music clearly. Clin. J. Am. Soc. Nephrol. 13, 1621–1623 (2018).
  Article PubMed PubMed Central Google Scholar
• Agrawal, L. et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 61, 295–299 (2018).
  Article PubMed Google Scholar
• Wong, M. G. et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39, 694–700 (2016).
  Article CAS PubMed Google Scholar
• Wyatt, C. M. & Cattran, D. C. Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes? Kidney Int. 90, 8–10 (2016).
  Article PubMed Google Scholar
• Folz, R. & Laiteerapong, N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 64, 2131–2137 (2021).
  Article PubMed PubMed Central Google Scholar
• Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
  Article CAS PubMed Google Scholar
• Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).
  Article CAS PubMed Google Scholar
• Echouffo-Tcheugui, J. B. et al. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT study. Diabetes Care 42, 486–493 (2019).
  Article PubMed PubMed Central Google Scholar
• Ceriello, A. et al. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. Cardiovasc. Diabetol. 21, 13 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Griffin, S. J., Leaver, J. K. & Irving, G. J. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60, 1620–1629 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
  Article Google Scholar
• Chow, E., Yang, A., Chung, C. H. L. & Chan, J. C. N. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer. Pharmaceuticals 15, 442 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, A. et al. Attenuated risk association of end-stage kidney disease with metformin in type 2 diabetes with eGFR categories 1-4. Pharmaceuticals 15, 1140 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Hong, J. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36, 1304–1311 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bergmark, B. A. et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Circulation 140, 1004–1014 (2019).
  Article CAS PubMed Google Scholar
• White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335 (2013).
  Article CAS PubMed Google Scholar
• Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326 (2013).
  Article CAS PubMed Google Scholar
• Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. JAMA 322, 1155 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015).
  Article CAS PubMed Google Scholar
• Rosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA 321, 69 (2019).
  Article CAS PubMed Google Scholar
• Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).
  Article CAS PubMed Google Scholar
• Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).
  Article CAS PubMed Google Scholar
• Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
  Article CAS PubMed Google Scholar
• Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
  Article CAS PubMed Google Scholar
• Giugliano, D. et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc. Diabetol. 20, 189 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018).
  Article CAS PubMed Google Scholar
• Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).
  Article CAS PubMed Google Scholar
• Kosiborod, M. et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J. Am. Coll. Cardiol. 71, 2628–2639 (2018).
  Article CAS PubMed Google Scholar
• McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
  Article CAS PubMed Google Scholar
• Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).
  Article PubMed Google Scholar
• Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
  Article CAS PubMed Google Scholar
• Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
  Article CAS PubMed Google Scholar
• Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28, 568–574 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117–128 (2021).
  Article CAS PubMed Google Scholar
• Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
  Article CAS PubMed Google Scholar
• Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
  Article CAS PubMed Google Scholar
• Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
  Article CAS PubMed Google Scholar
• EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2204233 (2022).
  Article Google Scholar
• Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes (CBER, 2008).
• Cefalu, W. T. et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 41, 14–31 (2018).
  Article CAS PubMed Google Scholar
• Hill, A. B. The environment and diseases: association or causation? Proc. R. Soc. Med. 58, 295–300 (1965).
  CAS PubMed PubMed Central Google Scholar
• Ke, C., Shah, B. R., Luk, A. O., Di Ruggiero, E. & Chan, J. C. N. Cardiovascular outcomes trials in type 2 diabetes: time to include young adults. Diabetes Obes. Metab. 22, 3–5 (2020).
  Article PubMed Google Scholar
• Jin, X. et al. Women’s participation in cardiovascular clinical trials from 2010 to 2017. Circulation 141, 540–548 (2020).
  Article PubMed Google Scholar
• Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
  Google Scholar
• Levin, A. et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int. 98, 849–859 (2020).
  Article PubMed Google Scholar
• Siew, E. D. et al. Timing of recovery from moderate to severe AKI and the risk for future loss of kidney function. Am. J. Kidney Dis. 75, 204–213 (2020).
  Article CAS PubMed Google Scholar
• Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P. & Shah, B. R. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat. Rev. Endocrinol. 18, 413–432 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Draznin, B. et al. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S144–S174 (2022).
  Article Google Scholar
• Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022).
  Article CAS PubMed Google Scholar
• Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255–323 (2020).
  Article PubMed Google Scholar
• Mahaffey, K. W. et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137, 323–334 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Codina, P. et al. Head-to-head comparison of contemporary heart failure risk scores. Eur. J. Heart Fail. 23, 2035–2044 (2021).
  Article CAS PubMed Google Scholar
• Shao, H. et al. Addressing regional differences in diabetes progression: global calibration for diabetes simulation model. Value Health 22, 1402–1409 (2019).
  Article PubMed PubMed Central Google Scholar
• Giorgino, F., Caruso, I., Moellmann, J. & Lehrke, M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, 154045 (2020).
  Article CAS PubMed Google Scholar
• Dave, C. V. et al. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation 143, 770–779 (2021).
  Article CAS PubMed Google Scholar
• Mancini, G. B. J. et al. 2022 Canadian Cardiovascular Society Guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can. J. Cardiol. 38, 1153–1167 (2022).
  Article PubMed Google Scholar
• Draznin, B. et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S175–S184 (2022).
  Article Google Scholar
• Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21, 968–974 (2018).
  Article Google Scholar
• So, W. Y. et al. Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes. Am. J. Manag. Care 9, 606–615 (2003).
  PubMed Google Scholar
• Pressman, A., Avins, A. L., Neuhaus, J., Ackerson, L. & Rudd, P. Adherence to placebo and mortality in the beta blocker evaluation of survival trial (BEST). Contemp. Clin. Trials 33, 492–498 (2012).
  Article PubMed PubMed Central Google Scholar
• van den Driessen Mareeuw, F., Vaandrager, L., Klerkx, L., Naaldenberg, J. & Koelen, M. Beyond bridging the know-do gap: a qualitative study of systemic interaction to foster knowledge exchange in the public health sector in the Netherlands. BMC Public Health 15, 922 (2015).
  Article PubMed PubMed Central Google Scholar
• Hunter, D. J. Meeting the challenge of the “Know-Do” gap comment on “CIHR Health System Impact Fellows: Reflections on ‘Driving Change’ Within the Health System”. Int. J. Health Policy Manag. 8, 498–500 (2019).
  Article PubMed PubMed Central Google Scholar
• Kazemian, P., Shebl, F. M., McCann, N., Walensky, R. P. & Wexler, D. J. Evaluation of the cascade of diabetes care in the United States, 2005–2016. JAMA Intern. Med. 179, 1376–1385 (2019).
  Article PubMed PubMed Central Google Scholar
• Chan, J. C. N. et al. From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions. Diabetes Care 42, 2022–2031 (2019).
  Article PubMed Google Scholar
• Van Spall, H. G. C., Fonarow, G. C. & Mamas, M. A. Underutilization of guideline-directed medical therapy in heart failure: can digital health technologies PROMPT change? J. Am. Coll. Cardiol. 79, 2214–2218 (2022).
  Article PubMed Google Scholar
• Nelson, A. J. et al. Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. J. Am. Heart Assoc. 10, e016835 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Mosenzon, O. et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc. Diabetol. 20, 154 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, J. C. What can we learn from the recent blood glucose lowering megatrials? J. Diabetes Investig. 2, 1–5 (2011).
  Article PubMed Google Scholar
• Eichler, H. G. et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10, 495–506 (2011).
  Article CAS PubMed Google Scholar
• Manne-Goehler, J. et al. Health system performance for people with diabetes in 28 low- and middle-income countries: a cross-sectional study of nationally representative surveys. PLoS Med. 16, e1002751 (2019).
  Article PubMed PubMed Central Google Scholar
• Lim, L. L. et al. Aspects of multicomponent integrated care promote sustained improvement in surrogate clinical outcomes: a systematic review and meta-analysis. Diabetes Care 41, 1312–1320 (2018).
  Article PubMed PubMed Central Google Scholar
• Hoo, J. X. et al. Impact of multicomponent integrated care on mortality and hospitalization after acute coronary syndrome: a systematic review and meta-analysis. Eur. Heart J. Qual. Care Clin. Outcomes https://doi.org/10.1093/ehjqcco/qcac032 (2022).
  Article PubMed Google Scholar
• Lim, L. L. et al. Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE Program: a retrospective cohort analysis. PLoS Med. 17, e1003367 (2020).
  Article PubMed PubMed Central Google Scholar
• Jiao, F. F. et al. Five-year cost-effectiveness of the multidisciplinary risk assessment and management programme-diabetes mellitus (RAMP-DM). Diabetes Care 41, 250–257 (2018).
  Article PubMed Google Scholar
• Wan, E. Y. F. et al. Five-year effectiveness of the multidisciplinary risk assessment and management programme-diabetes mellitus (RAMP-DM) on diabetes-related complications and health service uses-a population-based and propensity-matched cohort study. Diabetes Care 41, 49–59 (2018).
  Article PubMed Google Scholar
• Yeung, R. O. et al. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2, 935–943 (2014).
  Article CAS PubMed Google Scholar
• Ke, C. et al. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann. Intern. Med. 170, 145–154 (2019).
  Article PubMed Google Scholar
• Sattar, N. et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation 139, 2228–2237 (2019).
  Article PubMed Google Scholar
• Magliano, D. J. et al. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat. Rev. Endocrinol. 16, 321–331 (2020).
  Article PubMed Google Scholar
• Lim, L. L. et al. Effects of a technology-assisted integrated diabetes care program on cardiometabolic risk factors among patients with type 2 diabetes in the Asia-Pacific Region: the JADE program randomized clinical trial. JAMA Netw. Open 4, e217557 (2021).
  Article PubMed PubMed Central Google Scholar
• Chan, J. C. N. et al. Effect of a web-based management guide on risk factors in patients with type 2 diabetes and diabetic kidney disease: a JADE randomized clinical trial. JAMA Netw. Open 5, e223862 (2022).
  Article PubMed PubMed Central Google Scholar
• Nauck, M. A., Wefers, J. & Meier, J. J. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 9, 525–544 (2021).
  Article CAS PubMed Google Scholar
• Shah, N., Abdalla, M. A., Deshmukh, H. & Sathyapalan, T. Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Ther. Adv. Endocrinol. Metab. 12, 20420188211042145 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Barrera-Chimal, J. & Jaisser, F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes. Metab. 22 (Suppl. 1), 16–31 (2020).
  Article CAS PubMed Google Scholar
• Zhou, G., Johansson, U., Peng, X. R., Bamberg, K. & Huang, Y. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am. J. Transl. Res. 8, 1339–1354 (2016).
  CAS PubMed PubMed Central Google Scholar
• Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
  Article CAS PubMed Google Scholar
• Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).
  Article CAS PubMed Google Scholar
• Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989 (2021).
  Article CAS PubMed Google Scholar
• Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).
  Article CAS PubMed Google Scholar
• Samms, R. J., Coghlan, M. P. & Sloop, K. W. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol. Metab. 31, 410–421 (2020).
  Article CAS PubMed Google Scholar
• Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl Med. 5, 209ra151 (2013).
  Article PubMed Google Scholar
• Samms, R. J. et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J. Clin. Invest. 131, e146353 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Adriaenssens, A. E. et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 30, 987–996.e6 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
  Article CAS PubMed Google Scholar
• Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
  Article PubMed Google Scholar
• Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).
  Article CAS PubMed Google Scholar
• Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896–907 (2021).
  Article CAS PubMed Google Scholar
• Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).
  Article CAS PubMed Google Scholar